David L. Huso

21.6k citations

155 papers · 15.3k indexed · 6 hit papers · h-index 64

Cancer Research top 0.5%
Genetics top 0.2%
- Connective tissue disorders research 14
- Genetic and Kidney Cyst Diseases 9
- Virus-based gene therapy research 7
Biotechnology top 0.2%
Molecular Biology top 0.5%
- Cancer-related gene regulation 8
- Epigenetics and DNA Methylation 8
Oncology top 0.5%
- Cancer Cells and Metastasis 16
Hematology
- Acute Myeloid Leukemia Research 11
Pulmonary and Respiratory Medicine
- Aortic Disease and Treatment Approaches 9

Co-authors: Cynthia L. Sears Shaoguang Wu Bert Vogelstein Kenneth W. Kinzler Baktiar Karim Franck Housseau Xinqun Wu Harry C. Dietz
Cited by: Cancer Research Genetics Biotechnology
Journals: Nature (1 paper)Science (3 papers)Cell (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

David L. Huso

154 papers receiving 15.1k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2018 Science
2011 Proceedings of the National Academy of Sciences
2009 Nature Medicine
2006 Science
2005 Cancer Cell
1999 Journal of Clinical Investigation

Peers

Countries citing papers authored by David L. Huso

Since Specialization

Citations

This map shows the geographic impact of David L. Huso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Huso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Huso more than expected).

Fields of papers citing papers by David L. Huso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Huso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Huso. The network helps show where David L. Huso may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David L. Huso, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David L. Huso Line = papers co-authored together David L. Huso links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Oxytocin antagonism prevents pregnancy-associated aortic dissection in a mouse model of Marfan syndrome Science Translational Medicine ·Jennifer Habashi,Elena Gallo MacFarlane,Rustam Bagirzadeh,Caitlin J. Bowen,Nicholas D Huso,Yi‐Chun Chen,Djahida Bedja,Tyler J. Creamer,Graham Rykiel,Maurice Manning,David L. Huso,Harry C. Dietz	2019	38
2	Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteriabreakdown → Science ·Christine M. Dejea,Payam Fathi,John M. Craig,Annemarie Boleij,Rahwa Taddese,Abby L. Geis,Xinqun Wu,Christina E. DeStefano Shields,Elizabeth M. Hechenbleikner,David L. Huso,Robert A. Anders,Francis M. Giardiello,Elizabeth C. Wick,Hao Wang,Shaoguang Wu,Drew M. Pardoll,Franck Housseau,Cynthia L. Sears	2018	782
3	Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer Cancer Research ·Vanessa F. Merino,Nguyen Nguyen,Kideok Jin,Helen Sadik,Soonweng Cho,Preethi Korangath,Liangfeng Han,Yolanda M.N. Foster,Xian Zhou,Zhe Zhang,Roisín M. Connolly,Vered Stearns,Syed Z. Ali,Christina Adams,Qian Chen,Duojia Pan,David L. Huso,Peter Ordentlich,Angela Brodie,Saraswati Sukumar	2016	37
4	Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis Cancer Research ·Franck Housseau,Shaoguang Wu,Elizabeth C. Wick,Hongni Fan,Xinqun Wu,Nicolás J. Llosa,Kellie N. Smith,Ada Tam,Sudipto Ganguly,Jane W. Wanyiri,Thevambiga Iyadorai,Ausama A. Malik,April Camilla Roslani,Jamunarani S. Vadivelu,Sara Van Meerbeke,David L. Huso,Drew M. Pardoll,Cynthia L. Sears	2016	102
5	Reduction of Murine Colon Tumorigenesis Driven by Enterotoxigenic Bacteroides fragilis Using Cefoxitin Treatment PMC ·Christina E. DeStefano Shields,Sara W. Van Meerbeke,Franck Housseau,Hao Wang,David L. Huso,Robert A. Casero,Heather M. O’ Hagan,Cynthia L. Sears	2016	3
6	Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model Oncotarget ·Tara Williamson,Ren-Yuan Bai,Verena Staedtke,David L. Huso,Gregory J. Riggins	2016	62
7	Regulatory T-cell Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis Cancer Discovery ·Abby L. Geis,Hongni Fan,Xinqun Wu,Shaoguang Wu,David L. Huso,Jaime L. Wolfe,Cynthia L. Sears,Drew M. Pardoll,Franck Housseau	2015	142
8	The Notch Pathway Inhibits TGFβ Signaling in Breast Cancer through HEYL-Mediated Crosstalk Cancer Research ·Liangfeng Han,Adam Diehl,Nguyen K. Nguyen,Preethi Korangath,Wei Wen Teo,Soonweng Cho,Scott L. Kominsky,David L. Huso,Lionel Feigenbaum,Alan Rein,Pedram Argani,Göran Landberg,Manfred Gessler,Saraswati Sukumar	2014	27
9	Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways Oncogene ·P Wang,S-H Chen,W‐C Hung,C. Paul,Fei Zhu,P-P Guan,David L. Huso,Aikaterini Kontrogianni‐Konstantopoulos,Κωνσταντίνος Κωνσταντόπουλος	2014	48
10	53BP1 Is Limiting for NHEJ Repair in ATM-deficient Model Systems That Are Subjected to Oncogenic Stress or Radiation Molecular Cancer Research ·Ivana Rybanska-Spaeder,Taylor L. Reynolds,Jeremy Chou,Mansi Prakash,Tameca Jefferson,David L. Huso,Stephen Desiderio,Sonia Franco	2013	13
11	Genetic inactivation of AKT1 , AKT2 , and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation Proceedings of the National Academy of Sciences ·Kajsa Ericson,Christine Gan,Ian Cheong,Carlo Rago,Yardena Samuels,Victor E. Velculescu,Kenneth W. Kinzler,David L. Huso,Bert Vogelstein,Nickolas Papadopoulos	2010	106
12	Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) Journal of Neuroscience ·Eva Andrés‐Mateos,Rebeca Mejı́as,Masayuki Sasaki,Xiaojie Li,Brian M. Lin,Saskia Biskup,Li Zhang,Rebecca Banerjee,Bobby Thomas,Lichuan Yang,Guosheng Liu,M. Flint Beal,David L. Huso,Ted M. Dawson,Valina L. Dawson	2009	95
13	Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y Cancer Research ·Hong Song,Robert F. Hobbs,Ravy K. Vajravelu,David L. Huso,Caroline Esaias,Christos Apostolidis,Aliyah Morgenstern,George Sgouros	2009	118
14	Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts Molecular Cancer Therapeutics ·Francescopaolo Di Cello,Jöelle Hillion,Jeanne Kowalski,Brigitte M. Ronnett,Abimbola Aderinto,David L. Huso,Linda Resar	2008	26
15	The High-Mobility Group A1 Gene Up-Regulates Cyclooxygenase 2 Expression in Uterine Tumorigenesis Cancer Research ·Abeba Tesfaye,Francescopaolo Di Cello,Jöelle Hillion,Brigitte M. Ronnett,Ossama Elbahloul,Raheela Ashfaq,Surajit Dhara,Edward V. Prochownik,Kathryn Tworkoski,Raymond Reeves,Richard B.S. Roden,Lora H. Ellenson,David L. Huso,Linda Resar	2007	62
16	Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model Carcinogenesis ·Norman Peterson,Matthew D. Servinsky,Archie Christian,Zhongsheng Peng,Weiping Qiu,Jill F. Mann,J. F. Dicello,David L. Huso	2005	13
17	Mutant PIK3CA promotes cell growth and invasion of human cancer cellsbreakdown → Cancer Cell ·Yardena Samuels,Luis A. Díaz,Oleg Schmidt‐Kittler,Jordan M. Cummins,Laura J. DeLong,Ian Cheong,Carlo Rago,David L. Huso,Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein,Victor E. Velculescu	2005	727
18	CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction The Journal of Immunology ·Ching-Tai Huang,David L. Huso,Zhenbing Lu,Tianhong Wang,Gang Zhou,Eugene P. Kennedy,Charles G. Drake,David J. Morgan,Linda A. Sherman,Amy D. Higgins,Drew M. Pardoll,Adam J. Adler	2003	59
19	Combination bacteriolytic therapy for the treatment of experimental tumors Proceedings of the National Academy of Sciences ·Long H. Dang,Chetan Bettegowda,David L. Huso,Kenneth W. Kinzler,Bert Vogelstein	2001	446
20	Progressive Cerebellar, Auditory, and Esophageal Dysfunction Caused by Targeted Disruption of thefrizzled-4 Gene Journal of Neuroscience ·Yanshu Wang,David L. Huso,Hugh Cahill,David K. Ryugo,Jeremy Nathans	2001	121

About David L. Huso

David L. Huso is a scholar working on Genetics, Cancer Research and Oncology, having authored 155 papers that have together received 15.3k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (16 papers), Connective tissue disorders research (14 papers), Acute Myeloid Leukemia Research (11 papers), Aortic Disease and Treatment Approaches (9 papers), Genetic and Kidney Cyst Diseases (9 papers), Cancer-related gene regulation (8 papers), Epigenetics and DNA Methylation (8 papers) and Virus-based gene therapy research (7 papers). The work is most often cited by research in Cancer Research (2.2k citations), Genetics (4.0k citations) and Biotechnology (1.1k citations). David L. Huso has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Cynthia L. Sears, Shaoguang Wu, Bert Vogelstein, Kenneth W. Kinzler, Baktiar Karim, Franck Housseau, Xinqun Wu, Harry C. Dietz, Drew M. Pardoll and Shervin Rabizadeh. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact